



NEWS RELEASE

RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY AND SPECIALIZED PRESS IN MILAN

Milan, 27 April 2011 –Recordati S.p.A. will be hosting a meeting with the financial community and specialized press on:

Friday 6 May 2010 at 4.00 pm
Palazzo Mezzanotte
Piazza degli Affari, 6 – Milan

At the meeting Recordati's First Quarter 2011 results will be presented and the Group's development strategy and objectives for the period 2011-2013 will be discussed.

A simultaneous translation into English of the proceedings will be available via conference call. Dial-in numbers for the call in English and access ID are:

Italia	+39 064 521 7063
UK	+44 (0) 20 7136 2058
USA	+1 718 247 0884
Francia	+33 (0) 1 70994301
Germania	+49 (0) 69 5007 1309

ID to access the call in the English language: 3380664

A set of slides which will be referred to during the call will be available on our website: http://www.recordati.com/rec_en/investors/presentations/

Callers are invited to dial-in 10 minutes before conference time. If conference operator assistance is required during the connection please digit * followed by 0 or call +353 23 8832493. A recording of the conference call will be subsequently placed on the website:

http://www.recordati.com/rec_en/investors/presentations/

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of over 2,800, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. It has headquarters in Milan, Italy, operations in the main European countries, and a growing presence in the new markets of Central and Eastern Europe. A European field force of around 1,400 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. Consolidated revenue for 2010 was € 728.1 million, operating income was € 154.8 million and net income was € 108.6 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke

(39)0248787393

e-mail: inver@recordati.it

Media Relations

Claudio Rossetti (Echo Comunicazione d'Impresa)

(39)02 62694736

e-mail: crossetti@echocom.it

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.